Alumis CSO granted 216,675 stock options
Alumis Inc. reported a stock option grant to Chief Scientific Officer David M. Goldstein.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Alumis Inc. reported a stock option grant to Chief Scientific Officer David M. Goldstein. On January 26, 2026, he received an option to buy 216,675 shares of common stock at an exercise price of $26.31 per share, held as a direct derivative position.
According to the vesting terms, 25% of the shares underlying this option vest on January 26, 2027. The remaining shares vest in equal monthly installments over the following 36 months, contingent on his continued service under the company’s 2024 Equity Incentive Plan.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (Right to Buy) | 216,675 | $0.00 | $0.00 |
Footnotes (1)
- F1. 25% of the shares underlying this option vest on January 26, 2027, and the remaining shares vest in equal monthly installments thereafter over the following 36 months, subject to acceleration and the Reporting Person's Continuous Service (as defined in the Issuer's 2024 Equity Incentive Plan) to the Issuer on each such vesting date.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did Alumis (ALMS) disclose in this Form 4 filing?
How many stock options did Alumis grant to its Chief Scientific Officer?
What is the exercise price of the Alumis stock options reported for ALMS?
When do the Alumis (ALMS) stock options for the CSO start vesting?
What ongoing service conditions apply to the Alumis CSO’s stock options?
Is the Alumis Chief Scientific Officer’s stock option holding direct or indirect?
AI-generated analysis. How Rhea-AI works. Not financial advice.